全文获取类型
收费全文 | 1601003篇 |
免费 | 133603篇 |
国内免费 | 2583篇 |
专业分类
耳鼻咽喉 | 21653篇 |
儿科学 | 52957篇 |
妇产科学 | 46266篇 |
基础医学 | 228001篇 |
口腔科学 | 47257篇 |
临床医学 | 141092篇 |
内科学 | 314980篇 |
皮肤病学 | 34112篇 |
神经病学 | 130244篇 |
特种医学 | 64778篇 |
外国民族医学 | 474篇 |
外科学 | 243923篇 |
综合类 | 39743篇 |
现状与发展 | 3篇 |
一般理论 | 544篇 |
预防医学 | 122974篇 |
眼科学 | 36489篇 |
药学 | 121360篇 |
3篇 | |
中国医学 | 2976篇 |
肿瘤学 | 87360篇 |
出版年
2018年 | 14788篇 |
2016年 | 12917篇 |
2015年 | 15056篇 |
2014年 | 20693篇 |
2013年 | 31405篇 |
2012年 | 42614篇 |
2011年 | 44836篇 |
2010年 | 26380篇 |
2009年 | 25336篇 |
2008年 | 43055篇 |
2007年 | 45313篇 |
2006年 | 46111篇 |
2005年 | 44750篇 |
2004年 | 44144篇 |
2003年 | 42221篇 |
2002年 | 41341篇 |
2001年 | 75708篇 |
2000年 | 78367篇 |
1999年 | 66419篇 |
1998年 | 17745篇 |
1997年 | 16346篇 |
1996年 | 16327篇 |
1995年 | 16028篇 |
1994年 | 15078篇 |
1993年 | 14232篇 |
1992年 | 55464篇 |
1991年 | 53799篇 |
1990年 | 52590篇 |
1989年 | 50860篇 |
1988年 | 47239篇 |
1987年 | 46571篇 |
1986年 | 44303篇 |
1985年 | 42857篇 |
1984年 | 32047篇 |
1983年 | 27586篇 |
1982年 | 16158篇 |
1981年 | 14446篇 |
1980年 | 13571篇 |
1979年 | 30475篇 |
1978年 | 21072篇 |
1977年 | 17770篇 |
1976年 | 16707篇 |
1975年 | 17589篇 |
1974年 | 21496篇 |
1973年 | 20684篇 |
1972年 | 18864篇 |
1971年 | 17777篇 |
1970年 | 16298篇 |
1969年 | 15275篇 |
1968年 | 13958篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Kinase alterations are increasingly recognised as oncogenic drivers in mesenchymal tumours. Infantile fibrosarcoma and the related renal tumour, congenital mesoblastic nephroma, were among the first solid tumours shown to harbour recurrent tyrosine kinase fusions, with the canonical ETV6::NTRK3 fusion identified more than 20 years ago. Although targeted testing has long been used in diagnosis, the advent of more robust sequencing techniques has driven the discovery of kinase alterations in an array of mesenchymal tumours. As our ability to identify these genetic alterations has improved, as has our recognition and understanding of the tumours that harbour these alterations. Specifically, this study will focus upon mesenchymal tumours harbouring NTRK or other kinase alterations, including tumours with an infantile fibrosarcoma-like appearance, spindle cell tumours resembling lipofibromatosis or peripheral nerve sheath tumours and those occurring in adults with a fibrosarcoma-like appearance. As publications describing the histology of these tumours increase so, too, do the variety kinase alterations reported, now including NTRK1/2/3, RET, MET, RAF1, BRAF, ALK, EGFR and ABL1 fusions or alterations. To date, these tumours appear locally aggressive and rarely metastatic, without a clear link between traditional features used in histological grading (e.g. mitotic activity, necrosis) and outcome. However, most of these tumours are amenable to new targeted therapies, making their recognition of both diagnostic and therapeutic import. The goal of this study is to review the clinicopathological features of tumours with NTRK and other tyrosine kinase alterations, discuss the most common differential diagnoses and provide recommendations for molecular confirmation with associated treatment implications. 相似文献
2.
3.
4.
5.
Qian Zhang Larry D. Mesner Gina M. Calabrese Naomi Dirckx Zhu Li Angela Verardo Qian Yang Robert J. Tower Marie-Claude Faugere Charles R. Farber Thomas L. Clemens 《The Journal of clinical investigation》2021,131(7)
Bone mineral density (BMD) is a highly heritable predictor of osteoporotic fracture. GWAS have identified hundreds of loci influencing BMD, but few have been functionally analyzed. In this study, we show that SNPs within a BMD locus on chromosome 14q32.32 alter splicing and expression of PAR-1a/microtubule affinity regulating kinase 3 (MARK3), a conserved serine/threonine kinase known to regulate bioenergetics, cell division, and polarity. Mice lacking Mark3 either globally or selectively in osteoblasts have increased bone mass at maturity. RNA profiling from Mark3-deficient osteoblasts suggested changes in the expression of components of the Notch signaling pathway. Mark3-deficient osteoblasts exhibited greater matrix mineralization compared with controls that was accompanied by reduced Jag1/Hes1 expression and diminished downstream JNK signaling. Overexpression of Jag1 in Mark3-deficient osteoblasts both in vitro and in vivo normalized mineralization capacity and bone mass, respectively. Together, these findings reveal a mechanism whereby genetically regulated alterations in Mark3 expression perturb cell signaling in osteoblasts to influence bone mass. 相似文献
6.
7.
8.
9.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
10.
Major depressive disorder and other neuropsychiatric disorders are often managed with long-term use of antidepressant medication. Fluoxetine, an SSRI antidepressant, is widely used as a first-line treatment for neuropsychiatric disorders. However, fluoxetine has also been shown to increase the risk of metabolic diseases such as non-alcoholic fatty liver disease. Fluoxetine has been shown to increase hepatic lipid accumulation in vivo and in vitro. In addition, fluoxetine has been shown to alter the production of prostaglandins which have also been implicated in the development of non-alcoholic fatty liver disease. The goal of this study was to assess the effect of fluoxetine exposure on the prostaglandin biosynthetic pathway and lipid accumulation in a hepatic cell line (H4-II-E-C3 cells). Fluoxetine treatment increased mRNA expression of prostaglandin biosynthetic enzymes (Ptgs1, Ptgs2, and Ptgds), PPAR gamma (Pparg), and PPAR gamma downstream targets involved in fatty acid uptake (Cd36, Fatp2, and Fatp5) as well as production of 15-deoxy-Δ12,14PGJ2 a PPAR gamma ligand. The effects of fluoxetine to induce lipid accumulation were attenuated with a PTGS1 specific inhibitor (SC-560), whereas inhibition of PTGS2 had no effect. Moreover, SC-560 attenuated 15-deoxy-Δ12,14PGJ2 production and expression of PPAR gamma downstream target genes. Taken together these results suggest that fluoxetine-induced lipid abnormalities appear to be mediated via PTGS1 and its downstream product 15d-PGJ2 and suggest a novel therapeutic target to prevent some of the adverse effects of fluoxetine treatment. 相似文献